| scholarly article | Q13442814 |
| P2093 | author name string | M. L. Salgaller | |
| P. A. Lodge | |||
| P2860 | cites work | Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules | Q42010309 |
| New insights into the mobilization and phagocytic activity of dendritic cells | Q42142211 | ||
| Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells | Q42816165 | ||
| Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study | Q43405330 | ||
| Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells | Q44230547 | ||
| Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells | Q44615042 | ||
| Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma | Q45761361 | ||
| Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma | Q45880359 | ||
| Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma | Q46339324 | ||
| Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action | Q46365608 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors | Q50514753 | ||
| Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group | Q50999220 | ||
| Inhibition of cancer cell motility and invasion by interleukin-12. | Q53461580 | ||
| Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood | Q54451826 | ||
| Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor | Q56795686 | ||
| Antigen processing and presentation | Q58164117 | ||
| Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines | Q58409727 | ||
| Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study | Q61693105 | ||
| Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study | Q68093427 | ||
| A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes | Q68804520 | ||
| A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone | Q68815180 | ||
| Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma | Q69484555 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma | Q70508525 | ||
| Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance | Q70819752 | ||
| Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity | Q70852128 | ||
| A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma | Q71153705 | ||
| Duration of TCR stimulation determines costimulatory requirement of T cells | Q71400856 | ||
| DNA-based immunization by in vivo transfection of dendritic cells | Q71607054 | ||
| Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability | Q71615065 | ||
| Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer | Q71692727 | ||
| Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape | Q71762882 | ||
| Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Q71931319 | ||
| Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 | Q72052802 | ||
| Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside | Q72377535 | ||
| Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels | Q72710850 | ||
| Designing therapies that target tumor blood vessels | Q73038111 | ||
| Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and | Q73368715 | ||
| More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine | Q73368746 | ||
| Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease | Q73564882 | ||
| Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation | Q73734358 | ||
| Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition. | Q41274072 | ||
| In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy | Q41318025 | ||
| BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes | Q41371291 | ||
| Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay | Q41483145 | ||
| Antigens recognized by T-lymphocytes on human tumours | Q41505346 | ||
| Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice | Q41514824 | ||
| Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene | Q41525509 | ||
| Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein | Q41540719 | ||
| Tumor antigens recognized by T lymphocytes. | Q41573677 | ||
| Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 | ||
| Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes | Q41646787 | ||
| Inhibition of angiogenesis in vivo by interleukin 12. | Q41665801 | ||
| Target lysis by human lak cells is critically dependent upon target binding properties, but LFA-1, LFA-3 AND ICAM-1 are not the major adhesion ligands on targets | Q41698359 | ||
| Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells | Q41894129 | ||
| Antitumor and antimetastatic activity of interleukin 12 against murine tumors | Q41906195 | ||
| A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma | Q24307739 | ||
| Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation | Q24311763 | ||
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection | Q24561706 | ||
| Human neoplasms elicit multiple specific immune responses in the autologous host | Q24564371 | ||
| Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 | ||
| A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas | Q24679739 | ||
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes | Q24680097 | ||
| A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma | Q28296086 | ||
| Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals | Q28590979 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity | Q29619700 | ||
| The dendritic cell system and its role in immunogenicity | Q29619870 | ||
| Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. | Q30463850 | ||
| Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro | Q34246280 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans | Q34345458 | ||
| Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 | ||
| Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer | Q34437548 | ||
| The granulocyte-macrophage colony-stimulating factors | Q34564454 | ||
| Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy | Q35237202 | ||
| Molecular characterization of defective antigen processing in human prostate cancer. | Q36183805 | ||
| Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing | Q36231441 | ||
| Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells | Q36350884 | ||
| Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ | Q36352646 | ||
| Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells | Q36353721 | ||
| Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses | Q36362098 | ||
| The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas | Q36362111 | ||
| High efficiency retroviral mediated gene transduction into single isolated immature and replatable CD34(3+) hematopoietic stem/progenitor cells from human umbilical cord blood | Q36362618 | ||
| Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity | Q36362788 | ||
| Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes | Q36364355 | ||
| Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines | Q36364998 | ||
| Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes | Q36365159 | ||
| Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses | Q36365628 | ||
| A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene | Q36365847 | ||
| A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes | Q36365851 | ||
| Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? | Q36365923 | ||
| Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity | Q36366051 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo | Q36366124 | ||
| A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph | Q36366346 | ||
| Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions | Q36366583 | ||
| Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes | Q36366680 | ||
| A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma | Q36366872 | ||
| Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo | Q36367135 | ||
| Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells | Q36650065 | ||
| Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer | Q36745744 | ||
| Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes). | Q36791584 | ||
| Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen | Q36914397 | ||
| Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system | Q37340361 | ||
| Antigen recognition by class I-restricted T lymphocytes | Q38201551 | ||
| Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes | Q38310540 | ||
| Paracrine cytokine adjuvants in cancer immunotherapy | Q38574486 | ||
| Interleukin-2 in cancer treatment: disappointing or (still) promising? A review | Q39232767 | ||
| The human hematopoietic colony-stimulating factors | Q39656937 | ||
| Immunity to Oncogenic Proteins | Q40433308 | ||
| MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines | Q40433320 | ||
| Antigen presentation to cytotoxic T lymphocytes in vivo. | Q40468618 | ||
| Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? | Q40507181 | ||
| The role of adjuvant therapy in melanoma management | Q40559294 | ||
| Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant | Q40603879 | ||
| MHC ligands and peptide motifs: first listing | Q40612811 | ||
| Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma | Q40649818 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Phase I/II trial of autologous activated macrophages in advanced colorectal cancer | Q40662925 | ||
| IL-12: initiation cytokine for cell-mediated immunity | Q40709472 | ||
| T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl | Q40712555 | ||
| Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis | Q40746784 | ||
| Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects | Q40755408 | ||
| Tumor escape from immune response by variation in HLA expression and other mechanisms | Q40844521 | ||
| Dendritic cells: antigen presentation, accessory function and clinical relevance. | Q40850028 | ||
| Advances in systemic treatment of malignant melanoma | Q40877309 | ||
| The biochemistry and cell biology of antigen processing and presentation | Q40898211 | ||
| Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation | Q40968403 | ||
| Upstream-downstream: CD28 cosignaling pathways and T cell function | Q41010604 | ||
| Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope | Q41147370 | ||
| MHC class I-restricted CTL responses to exogenous antigens | Q41182483 | ||
| Measurement of prostate-specific membrane antigen in the serum with a new antibody | Q41212638 | ||
| Augmenting the immunogenicity of carbohydrate tumor antigens | Q41236231 | ||
| Selection of potent immunological adjuvants for vaccine construction | Q41236255 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 122-138 | |
| P577 | publication date | 1998-06-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Surgical Oncology | Q1919535 |
| P1476 | title | Use of cellular and cytokine adjuvants in the immunotherapy of cancer | |
| P478 | volume | 68 |
| Q38617351 | Advances in antitumor polysaccharides from phellinus sensu lato: Production, isolation, structure, antitumor activity, and mechanisms |
| Q33764666 | Advances in vaccine adjuvants |
| Q35219026 | Cancer vaccines: between the idea and the reality |
| Q36723147 | Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer |
| Q33631967 | Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene |
| Q45721971 | Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. |
| Q34267670 | Immunotherapy of metastasis. |
| Q44290945 | Liposomal delivery of antigen to human dendritic cells |
| Q35953762 | Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines |
| Q43844222 | Neural regulation of dendritic cell function |
| Q30418184 | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice |
| Q37812128 | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens |
| Q33997622 | Outlining novel cellular adjuvant products for therapeutic vaccines against cancer |
| Q46310803 | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| Q30327421 | Prostate cancer immunotherapy at the dawn of the new millennium. |
| Q46729949 | Purification and characterization of an antitumor polysaccharide from Portulaca oleracea L |
| Q34756188 | Recent advances in vaccine adjuvants |
| Q34376294 | Recent developments in adjuvants for vaccines against infectious diseases |
| Q40431424 | Recombinant NDV expressing cytokines or fliC confers a quick immune response against NDV challenge and resistance to maternal antibody |
| Q73265616 | Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials |
| Q37527497 | Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system |
| Q54459294 | Sympathetic nervous system influence on the innate immune response |
| Q73009798 | The dendritic cell and human cancer vaccines |
| Q34560660 | The development of immunotherapies for non-small cell lung cancer |
| Q74672097 | The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis |
| Q36194084 | The role of adjuvants in the development of mucosal vaccines |
Search more.